Pasithea Therapeutics (KTTA) Cash from Financing Activities (2021 - 2026)
Pasithea Therapeutics recorded quarterly Cash from Financing Activities of $750.0 in Q1 2026, down 100.0% quarter-over-quarter from $56.4 million in Q4 2025, and down 99.95% year-over-year from $1.5 million in Q1 2025.
Pasithea Therapeutics' Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $750.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 99.95% year-over-year to $750.0; the TTM figure through Mar 2026 stood at $62.0 million (up 2675.57% YoY), while the FY2025 annual figure was $63.5 million, up 1306.02% from the prior year.
- Cash from Financing Activities came in at $750.0 for Q1 2026 at Pasithea Therapeutics, down from $56.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $56.4 million in Q4 2025 to a low of -$3.9 million in Q3 2023.
- A 4-year average of $6.6 million and a median of $750.0 in 2026 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities soared 239682.21% in 2025 and slumped 99.95% in 2026, its largest moves.
- Pasithea Therapeutics' Cash from Financing Activities stood at -$3.9 million in 2023, then jumped by 99.39% to -$23550.0 in 2024, then jumped by 239682.21% to $56.4 million in 2025, then tumbled by 100.0% to $750.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $750.0, $56.4 million, and -$116145.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | 750.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 750.00 |
| Mar 31, 2026 | 750.00 |
| Dec 31, 2025 | 56.42 Mn |
| Dec 31, 2025 | 56.42 Mn |
| Sep 30, 2025 | -116,145.00 |
| Sep 30, 2025 | -116,145.00 |
| Jun 30, 2025 | 5.74 Mn |
| Jun 30, 2025 | 5.74 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Dec 31, 2024 | -23,550.00 |
| Dec 31, 2024 | -23,550.00 |
| Sep 30, 2023 | -3.86 Mn |
| Sep 30, 2023 | -3.86 Mn |
| Jun 30, 2023 | -130,768.00 |
| Jun 30, 2023 | -130,768.00 |
| Mar 31, 2023 | 264,103.00 |
| Mar 31, 2023 | 264,103.00 |
| Dec 31, 2021 | 34.17 Mn |
| Dec 31, 2021 | 34.17 Mn |
| Sep 30, 2021 | 20.55 Mn |
| Sep 30, 2021 | 20.55 Mn |
| Mar 31, 2021 | 1.21 Mn |
| Mar 31, 2021 | 1.21 Mn |